CSTL Logo

Castle Biosciences, Inc. (CSTL) 

NASDAQ
Market Cap
$809.69M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
503 of 774
Rank in Industry
32 of 42

Largest Insider Buys in Sector

CSTL Stock Price History Chart

CSTL Stock Performance

About Castle Biosciences, Inc.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test …

Insider Activity of Castle Biosciences, Inc.

Over the last 12 months, insiders at Castle Biosciences, Inc. have bought $0 and sold $10.34M worth of Castle Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Castle Biosciences, Inc. have bought $49,058 and sold $95.35M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,800 shares for transaction amount of $69,004 was made by Goldberg Ellen (director) on 2023‑06‑05.

List of Insider Buy and Sell Transactions, Castle Biosciences, Inc.

2024-11-15SaleChief Financial Officer
6,923
0.0241%
$29.93$207,217+1.25%
2024-11-12SalePres. & Chief Exec. Officer
4,529
0.0169%
$34.15$154,665-13.21%
2024-11-05SaleChief Commercial Officer
3,507
0.0132%
$35.56$124,7090.00%
2024-11-04SalePres. & Chief Exec. Officer
4,529
0.0156%
$32.54$147,362-2.73%
2024-11-01SaleChief Commercial Officer
3,100
0.0119%
$35.39$109,709-1.12%
2024-11-01Saledirector
6,442
0.0243%
$34.73$223,755-1.12%
2024-10-14SalePres. & Chief Exec. Officer
4,529
0.0188%
$32.27$146,164-3.04%
2024-10-08SalePres. & Chief Exec. Officer
2,264
0.0088%
$30.27$68,529+10.31%
2024-10-07Saledirector
6,442
0.0244%
$29.44$189,672+11.99%
2024-10-04SalePres. & Chief Exec. Officer
2,265
0.0084%
$28.73$65,083+12.16%
2024-09-16SalePres. & Chief Exec. Officer
4,529
0.0163%
$30.97$140,272+1.68%
2024-09-11SalePres. & Chief Exec. Officer
2,296
0.0086%
$30.32$69,6150.00%
2024-09-09SalePres. & Chief Exec. Officer
2,286
0.0083%
$29.46$67,339+6.55%
2024-09-05Saledirector
6,442
0.0229%
$29.02$186,973+5.77%
2024-09-04SalePres. & Chief Exec. Officer
700
0.0026%
$30.02$21,017+7.45%
2024-09-03SaleChief Operating Officer
5,832
0.021%
$29.21$170,330+6.07%
2024-09-03SalePres. & Chief Exec. Officer
980
0.0036%
$30.05$29,447+6.07%
2024-08-30SalePres. & Chief Exec. Officer
755
0.0028%
$30.10$22,725+3.86%
2024-08-29SalePres. & Chief Exec. Officer
2,928
0.0107%
$30.07$88,060+2.99%
2024-08-26SalePres. & Chief Exec. Officer
180
0.0007%
$30.05$5,409+5.53%

Insider Historical Profitability

24.1%
MGC Venture Partners 2013 GP, LLC10 percent owner
1464020
5.2273%
$28.9113+21.26%
Sofinnova HealthQuest Partners, L.P.
1433577
5.1186%
$28.9118+21.26%
KABAKOFF DAVID Sdirector
503577
1.798%
$28.91129+21.26%
Cook Joseph C. IIIdirector
112178
0.4005%
$28.91146+21.26%
Aspinall Mara G.director
30848
0.1101%
$28.9114+21.26%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$57.49M9.42.6M+13.69%+$6.92M<0.01
Wasatch Advisors$56.51M9.242.55M-1.54%-$882,965.450.3
Granahan Investment Management$36.04M5.891.63M-24.89%-$11.94M1.27
The Vanguard Group$33.1M5.411.49M+2.24%+$724,194.24<0.01
Bellevue Group$27.02M4.421.22M-1%-$272,289.950.41
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.